Research programme: glutaminyl-peptide cyclotransferase modulators - 858 Therapeutics
Alternative Names: Research programme: QPCT/L modulators - 858 TherapeuticsLatest Information Update: 27 Dec 2023
At a glance
- Originator 858 Therapeutics
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action Glutaminyl-peptide cyclotransferase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atherosclerosis; Neurodegenerative disorders
Most Recent Events
- 19 Dec 2023 Preclinical trials in Atherosclerosis in USA (unspecified route) (858 therapeutics pipeline; December 2023)
- 19 Dec 2023 Preclinical trials in Neurodegenerative disorders in USA (unspecified route) (858 therapeutics pipeline; December 2023)